{
    "clinical_study": {
        "@rank": "8148", 
        "acronym": "PACER", 
        "arm_group": {
            "arm_group_label": "Panitumumab", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess if panitumumab is active enough to warrant\n      comparative studies in patients with metastatic colorectal cancer that has progressed after\n      treatment with cetuximab."
        }, 
        "brief_title": "A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologic diagnosis of metastatic colorectal adenocarcinoma\n\n          -  A wild-type tumor KRAS gene determined from tumor DNA\n\n          -  Failure from previous treatment with fluoropyrimidine, oxaliplatin and irinotecan.\n             Patients may or may not have been treated with bevacizumab.\n\n          -  Documented disease progression following a treatment with cetuximab in patients who\n             showed either an objective response after 8 weeks or stable disease after 16 weeks of\n             cetuximab treatment.\n\n          -  Age at least 18 years\n\n          -  ECOG Performance Status 0-2\n\n          -  Neutrophils at least 1,500 mm3, platelets at least 100,000 mm3, and hemoglobin at\n             least 9 g/dL\n\n          -  Bilirubin level less than 1.5 times ULN\n\n          -  AST (SGOT) and ALT (SGPT) not greater than 2.5 times ULN (or 5 times ULN in presence\n             of liver metastasis)\n\n          -  Serum creatinine less than 1.5 times ULN\n\n          -  Effective contraception, if the risk of conception exists\n\n          -  Life expectancy at least 3 months\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Symptomatic brain metastasis\n\n          -  Interstitial pneumonitis or pulmonary fibrosis\n\n          -  Any other malignancies within 5 years (except for adequately treated carcinoma in\n             situ of the cervix or non melanoma skin cancer)\n\n          -  Chemotherapy, radiotherapy or immunotherapy within the past 4 weeks\n\n          -  Any unstable systemic disease (including active infections, any significant hepatic,\n             renal or metabolic disease), metabolic dysfunction, physical examination finding, or\n             clinical laboratory finding that contraindicates the use of study drugs or render the\n             patient at high risk from treatment complications\n\n          -  Subject pregnant or breast feeding, or planning to become pregnant within 6 months\n             after the end of treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01801904", 
            "org_study_id": "PACER", 
            "secondary_id": "2010-024490-39"
        }, 
        "intervention": {
            "arm_group_label": "Panitumumab", 
            "description": "6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity", 
            "intervention_name": "Panitumumab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies, Monoclonal", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "cetuximab-refractory", 
        "lastchanged_date": "January 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Benevento", 
                        "country": "Italy", 
                        "state": "BN"
                    }, 
                    "name": "Azienda Ospedaliera G. Rummo"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Benevento", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Fatebenefratelli"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Nazionale dei Tumori"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy"
                    }, 
                    "name": "A.O.U. Policlinico Federico II"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S. Giovanni Rotondo", 
                        "country": "Italy"
                    }, 
                    "name": "Casa Sollievo Sofferenza"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer", 
        "other_outcome": {
            "description": "exploratory analysis of tumor-tissue for biological or genomic determinants of outcome (N-ras, BRAF and P13K mutation status, EGFR and PTEN expression status", 
            "measure": "gene expression on tumor tissue", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "overall_contact": {
            "email": "francesco.perrone@usc-intnapoli.net", 
            "last_name": "Francesco Perrone, M.D., Ph.D.", 
            "phone": "+39 081 5903571"
        }, 
        "overall_contact_backup": {
            "email": "marilina.piccirillo@usc-intnapoli.net", 
            "last_name": "Maria Carmela Piccirillo, M.D.", 
            "phone": "+39 081 5903615"
        }, 
        "overall_official": [
            {
                "affiliation": "Azienda Sanitaria Rummo, Benevento, Division of Medical Oncology", 
                "last_name": "Bruno Daniele, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National Cancer Institute Naples, Italy;  Director Clinical Trials Unit", 
                "last_name": "Francesco Perrone, M.D., Ph.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Second University of Naples, Italy; Chair of Medical Statistics", 
                "last_name": "Ciro Gallo, M.D., Ph.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universit\u00e0 Cattolica del S. Cuore, Policlinico Gemelli, Roma", 
                "last_name": "Antonio Gasbarrini, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ospedale Antonio Cardarelli, Napoli", 
                "last_name": "Giacomo Carteni', M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "progression of disease within 2 months from registration according to RECIST criteria, and death for any cause within 2 months from registration", 
            "measure": "number of patients alive and without disease progression", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01801904"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response assessed per patients at weeks 8,16,24,32,40 and every 3 months thereafter, using RECIST criteria", 
                "measure": "response rate", 
                "safety_issue": "No", 
                "time_frame": "up to 40 weeks"
            }, 
            {
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "worst grade toxicity (according to Common Terminology Criteria for Adverse Events version 3) per patient", 
                "measure": "worst grade toxicity per patient", 
                "safety_issue": "Yes", 
                "time_frame": "every 2 weeks for up to 6 months"
            }
        ], 
        "source": "National Cancer Institute, Naples", 
        "sponsors": {
            "collaborator": {
                "agency": "Azienda Ospedaliera G. Rummo", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Cancer Institute, Naples", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}